CKD carries cardiovascular risk equivalent to established coronary disease — yet most patients never connect their kidney numbers to their cardiac risk. This guide explains the bidirectional relationship, what your eGFR and uACR mean for your heart, and which treatments protect both organs.
Most patients with chronic kidney disease are managed with a focus on preserving kidney function. What frequently goes underemphasized: the leading cause of death in CKD is not kidney failure — it is cardiovascular disease. CKD stage 3+ carries cardiovascular risk equivalent to established coronary artery disease.
This guide ensures you understand both sides of the cardio-renal axis, know what your kidney numbers mean for your heart, and can have an informed conversation about the medications that now protect both organs simultaneously.
All 6 CKD stages with eGFR ranges, kidney function description, and cardiovascular risk implication for each.
Hypertension, uremic toxins, anemia, mineral disorder, dyslipidemia, and systemic inflammation — how each works.
eGFR and uACR thresholds, what changes demand action, and monitoring frequency for cardiac patients with CKD.
CREDENCE, DAPA-CKD, EMPA-KIDNEY — the trials that showed 30-40% eGFR decline reduction and cardiac benefit.
ACE inhibitor + diuretic + NSAID — the combination that causes acute kidney injury, and what to take for pain instead.
The new non-steroidal MRA that reduces both CKD progression and cardiovascular events in diabetic kidney disease.
“CKD is a cardiovascular risk condition. Full stop. Patients with even moderate kidney disease should receive the same intensity of cardiovascular risk management as patients with established heart disease. The organs are one system — we protect them together.”
The cardio-renal connection most patients and many physicians underestimate.
Get Kidney-Heart Guide — $37